{
    "nct_id": "NCT03878849",
    "official_title": "Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®",
    "inclusion_criteria": "* Signed informed consent form\n* Age 18 years or older\n* Histologically or cytological documented ovarian carcinoma with ≥ 2 or more previous chemotherapies including potential treatment with other PARP inhibitors (PARPi)\n* Platinum free interval of ≥ 3 month\n* Measurable disease by CT scan or MRI\n* A 2X-121 DRP® using Fixed in Formalin and Embedded in Paraffin (FFPE) archival or the latest tumor tissue with an outcome measured as being in the upper 50% likelihood of response\n* Performance status of ECOG ≤ 1\n* Patients must have a life expectancy of >16 weeks\n* Recovered to Grade 1 or less from prior surgery or acute toxicities of prior radiotherapy, or treatment with cytotoxic, hormonal or biologic agents\n* Adequate conditions and protocol values of the following clinical laboratory parameters:\n\n  1. Absolute neutrophils count\n  2. Hemoglobin\n  3. Platelets\n  4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\n  5. Serum bilirubin\n  6. Alkaline phosphatase\n  7. Creatinine\n  8. Blood urea within normal limits\n* FFPEs tumor tissue should be available either from primary surgery or later\n* Negative serum pregnancy test in women of childbearing potential (WOCBP).\n* Women of childbearing age and potential must be willing to use adequate effective contraception during the study and a period after last dose of study drug\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently participating in or having participated in a study of an investigational agent or using an investigational device within 2 weeks of giving informed consent\n* Concurrent chemotherapy, radiotherapy, or hormonal therapy for the disease under investigation\n* Other malignancy with exception of any stage I and II cancer that is deemed cured or deemed not to influence the overall survival by the Investigator\n* Any active infection still requiring parenteral or oral antibiotic treatment\n* Known HIV positivity\n* Known active hepatitis B or C\n* Clinical significant (i.e. active) cardiovascular disease:\n\n  1. Stroke within ≤ 6 months prior to day 1\n  2. Transient ischemic attack (TIA) within ≤ 6 months prior to day 1\n  3. Myocardial infarction within ≤ 6 months prior to day 1\n  4. Unstable angina\n  5. New York Hart Association (NYHA) Grade II or greater congestive heart failure (CHF)\n  6. Serious cardiac arrhythmia requiring medication\n* Other medications or conditions that in the investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhoea, or vomiting) that might impair the bioavailability of 2X-121\n* Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy\n* Patients unable to be regularly followed for any reason (geographic, familiar, social, psychologic, housed in an institution eg. prison because of a court agreement or administrative order)\n* Subjects that are depending on the sponsor/CRO or investigational site as well as on the investigator",
    "miscellaneous_criteria": ""
}